News Sanofi plans amlitelimab dermatitis filing after new readout Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
